Navigation Links
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Date:4/16/2010

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achiev
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
2. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
3. Treatment for chronic hepatitis C: A phase II study
4. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
5. InstaMed Achieves Core Phase II Certification to Streamline Provider Access to Consistent Electronic Eligibility and Claim Status
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. Aetna and WellPoint Achieve CORE Phase II Certification
8. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum
11. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team ... The University of Texas Health Science Center at San ... the structure of a protein that helps a common ... Candida albicans causes yeast infections, diaper rashes ... pathogen to infect humans. It can also cause a ...
(Date:4/15/2014)... Scientists have solved a decades-old medical mystery and ... to fight invasive fungal infections, which kill about 1.5 million ... mechanism of action of amphotericin, an antifungal drug that has ... though it is nearly as toxic to human cells as ... report of the new findings appears in Nature ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April ... using a novel way to access the heart. ... the United States performing the unique procedure called ... temporarily connecting major blood vessels. , Northern Michigan ... transcaval procedure on July 3, 2013 when traditional ...
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2
... multiple low-energy treatments, combined with a plasma skin regeneration ... appearance, in record healing time. These multiple treatments have ... reduced healing times. ,"Plasma is a unique ... atoms to form an ionized gas," the authors write ...
... 27,000 women adds support to the view that high cholesterol ... even in healthy women with no history of heart disease ... importance of cholesterol levels as a risk factor for stroke, ... are otherwise healthy,” said study author Tobias Kurth, MD, ScD, ...
... over the influence of scantily clad dolls on young minds, ... one important reason for the rise of eating disorders, they ... voiced apprehension regarding the hype created by the media about ... which are known for their hour glass figures and revealing ...
... found evidence that a genetic tendency toward suicide has ... on chromosome 2. The same has been implicated in ... ,“We’re hoping our findings will eventually lead to tests ... suicide,” says Virginia Willour, Ph.D., an assistant professor in ...
... in women years in advance of a medical diagnosis ... ,Epidemiologists at the University at Buffalo in New ... diabetes found in the blood, such as markers of ... are present early on in women who eventually progress ...
... Otolaryngology-Head & Neck Surgery, chronic dizziness may be attributed// to ... study investigated 345 men and women who had suffered dizziness ... the age group of 15 to 89. It was found ... kind of anxiety disorders like migraine or a serious brain ...
Cached Medicine News:Health News:Multiple Low-energy Plasma Skin Treatments Beneficial in Reducing Facial Wrinkles 2Health News:Study Links Attempted Suicide With Genetic Evidence 2Health News:Study Links Attempted Suicide With Genetic Evidence 3Health News:Diabetes Risk Factors Develop Earlier in Women Than Men 2
(Date:1/15/2014)... -- Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer ... VPHM).   As a result of the waiver, ... Shire expects to complete the tender offer on January 24, ... satisfaction of all of the remaining conditions to the tender ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: